• By ICR Secretariat
  • Posted Thursday, August 4, 2022

Aiming to avoid Pfizer's Eucrisa failure, Arcutis wins FDA nod for Zoryve cream in psoriasis


Pfizer once harbored blockbuster hopes for Eucrisa to be the next big topical treatment for inflammatory skin diseases. But the ointment never gained traction thanks to side effects and reimbursement hurdles. Now, young biotech Arcutis Biotherapeutics is bringing along a new therapy that goes after the same drug target but with a very different product profile.